VBI Vaccines (NASDAQ:VBIV) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.
Insider and Institutional Ownership
53.0% of VBI Vaccines shares are held by institutional investors. Comparatively, 73.5% of Merck & Co., Inc. shares are held by institutional investors. 16.2% of VBI Vaccines shares are held by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares VBI Vaccines and Merck & Co., Inc.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Merck & Co., Inc.||14.71%||36.83%||13.72%|
Volatility and Risk
VBI Vaccines has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.
This is a summary of current ratings and target prices for VBI Vaccines and Merck & Co., Inc., as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Merck & Co., Inc.||0||4||10||0||2.71|
VBI Vaccines currently has a consensus price target of $10.50, indicating a potential upside of 432.99%. Merck & Co., Inc. has a consensus price target of $77.44, indicating a potential upside of 5.81%. Given VBI Vaccines’ stronger consensus rating and higher probable upside, research analysts plainly believe VBI Vaccines is more favorable than Merck & Co., Inc..
Merck & Co., Inc. pays an annual dividend of $2.20 per share and has a dividend yield of 3.0%. VBI Vaccines does not pay a dividend. Merck & Co., Inc. pays out 50.7% of its earnings in the form of a dividend. Merck & Co., Inc. has increased its dividend for 7 consecutive years.
Valuation and Earnings
This table compares VBI Vaccines and Merck & Co., Inc.’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|VBI Vaccines||$3.36 million||57.26||-$63.60 million||($0.97)||-2.03|
|Merck & Co., Inc.||$42.29 billion||4.67||$6.22 billion||$4.34||16.86|
Merck & Co., Inc. has higher revenue and earnings than VBI Vaccines. VBI Vaccines is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.
Merck & Co., Inc. beats VBI Vaccines on 11 of the 17 factors compared between the two stocks.
VBI Vaccines Company Profile
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus. It is also developing cytomegalovirus vaccine candidate for infectious disease; and glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts.
Merck & Co., Inc. Company Profile
Merck & Co., Inc. provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, and cervical cancer, as well as brain tumors; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; fertility management products for horses; vaccines for dogs, cats, and horses; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; and Eisai Co., Ltd. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.